Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Ev3's Pipeline: Firm completes modular PMA application for its Pipeline embolization device to treat uncoilable or failed aneurysms, announced May 18. Ev3 says it anticipates an FDA advisory panel review of the endovascular treatment "sometime later in the year" and U.S. approval in 2011. Ev3 acquired the self-expanding cylindrical mesh implant through its purchase of Chestnut Medical Technologies in 2009 (1"The Gray Sheet" June 8, 2009)

You may also be interested in...



News In Brief

Utah Medical buys Femcare

News In Brief

Utah Medical buys Femcare

Alcon To Launch LenSx Cataract Surgery Laser In Q4 Following Acquisition

Alcon will launch a femtosecond laser system for cataract surgery in the fourth quarter after acquiring technology developer LenSx Lasers

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

See All
UsernamePublicRestriction

Register

MT028920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By